Upperton’s new R&D facility receives MHRA approval

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/psisa)
(Image: Getty/psisa)

Related tags: Mhra, Biotherapeutics, Research and development, Gmp, Clinical trials, Manufacturing

Upperton Pharma’s new and expanded facilities received a positive inspection from MHRA, enabling both research and development and clinical manufacturing at the site.

Upperton Pharma Solutions’ new pharmaceutical manufacturing facilities at Nottingham Science and Technology Park have successfully passed inspection by the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Upperton pharmaceutical, a contract development and manufacturing organization (CDMO), had moved to new facilities in March of 2018. This move to Nottingham from its previous headquarters at BioCity was part of the company’s planned expansion.

The new facilities boost enhancements and expansions of the company’s processing and analytical capabilities.

After the MHRA provided its inspection and deemed the facility as passing, Upperton now has the necessary licenses for manufacture, downstream processing into capsules and tablets, and the release of spray-dried formulations of biotherapeutics and small molecule APIs for use in clinical trials.

Additionally, the company can now develop pharmaceutical formulations for oral, nasal, and pulmonary delivery from early feasibility studies to Phase I and II clinical manufacture.

Richard Johnson, CEO of Upperton Pharma Solutions said in a statement that this endorsement by the MHRA will enable Upperton to have a “seamless transition from [research and development] R&D to [good manufacturing practice] GMP manufacture”​ which will guarantee that all project-specific information developed in research and development will “flow through to GMP manufacturing processes.”

Related news

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Related suppliers

Follow us


View more